News AZ's Tagrisso gets full US approval in lung cancer Phase 3 data confirmed its efficacy in patients with a certain mutation.
News Tesaro's niraparib approved in ovarian cancer Company nabs maintenance therapy use, but problems on breast cancer trial.
News Real world data will help AZ's Farxiga in cardio battle AZ hopes data will boost sales of its Farxiga.
News NICE rejects Darzalex, citing lack of clinical evidence NICE has rejected Janssen’s Darzalex (daratumumab) for regular NHS funding in third line multiple myeloma, saying that gaps in clinical evidence mean cost-effectiveness data are unreliable.
News AZ strikes COPD deal with Circassia, suffers setback with bl... FDA rejects blood potassium drug for second time.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
